Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Import to Russia (July 2022)

Monday, September 5, 2022

In January–July 2022, Russia imported 459.4 billion rubles’ worth of ready-made pharmaceutical drugs (customs clearance and VAT included), up 6% from the same period in 2021. As for bulk drugs, the growth rate was 25.6%. In physical terms, the growth rates for both groups were negative. The import volume of ready-made drugs was around 942 million packages, down 10.2% from January–July 2021. If calculated in minimum dosage units (MDU), the import volume of ready-made drugs was 18.2 billion MDUs, down 12.2%. The growth rate of the import of bulk drugs was –32.4% in MDUs, with 903.2 million MDUs imported.

The July results differed from June in both short-term and long-term growth rates. The import of ready-made drugs in July 2022 went down 9.2% in rubles from July 2021, and that of bulk drugs dropped 17.7%. In physical terms, the import of ready-made pharmaceuticals dropped by 14.7%, while that of bulk drugs shrank by 30.8%. This is a result of the low activity in July 2022, as well as the large volumes in the comparison period.

Even with the market practically stagnating, many of the top importers had high growth rates in January–July 2022. Vertex Pharmaceuticals had the best growth rates among the top 20 manufacturers of ready-made drugs with the largest import volumes—its imports grew 13.6 times against January–July 2021. Vertex Pharmaceuticals is followed by AstraZeneca (imports grew 2.5 times). Trikafta and Orkambi, drugs for the treatment of cystic fibrosis, contributed to the growth rates of Vertex Pharmaceuticals, accounting for 96% of the total import volume. As for AstraZeneca, two cancer drugs, Lynparza and Coselugo, helped the company’s growth rates. Sarepta Therapeutics showed unprecedented growth rates among the companies outside the top 20—its imports increased 54 times against January–July 2021. It is quite obvious that the company imports drugs for the treatment of rare diseases, in particular, Exondys 51 and Vyondys 53—both are used for Duchenne muscular dystrophy and have not been approved in Russia yet.

As for the top manufacturers of bulk drugs, CSL Behring had the highest growth rates in January–July 2022—its imports grew 4.6 times against January–July 2021. The company imported two medications, but only hemostatic Haemate, packaged by Skopinoharm in Russia, helped the growth rates. Outside the top, Stada also increased its growth rates 4.6 times against January–July 2021. The company’s non-steroidal anti-inflammatory drug Bixitor, packaged at Hemofarm in Obninsk (Kaluga Oblast), contributed to the growth rates the most.

Growth rates of imports of pharmaceuticals to Russia (EEU countries excluded), free circulation prices, customs clearance and VAT included, RUB (January 2021–July 2022)